← Research & Industry News
External source
Kamau shares first data from revamped sickle cell gene editing therapy
Kamau Therapeutics, which has stayed relatively quiet since its 2023 emergence, is sharing clinical data from its revamped sickle cell gene editing program for the first time. The startup is giving a ...
- Published by
- Endpoints News
- Evidence type
- Laboratory
Kamau Therapeutics, which has stayed relatively quiet since its 2023 emergence, is sharing clinical data from its revamped sickle cell gene editing program for the first time. The startup is giving a ...
This item was selected automatically by our daily literature and news monitor because it matches the topics we follow. Read the full story at Endpoints News.
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.